Vaximm AG

SEOUL, South Korea, April 22, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical development resources and launch a strategic collaboration between the two companies. Through the MOU, the two companies will explore various ways to collaborate to create synergies between current platform technologies and new drug candidates. OSR Holdings was established in 2019 in South Korea as a "hub-and-spoke" business model, which has become more visible in the biopharma space over the past decade. The "hub-and-spoke" model, exemplified by companies like Roivant Sciences, PureTech Health and BridgeBio Pharma, enables centralized management of drug development strategies, clinical plans, and resource allocation by the holding company. The model allows the holding companies' subsidiaries to concentrate on the advancement of new drug assets and technological innovations. The model's scalability and resource efficiency are notably enhanced, especially as clinical phases of drug development progresses. OSR Holdings' current portfolio includes Vaximm AG, a Swiss entity developing immuno-oncology therapeutics; Darnatein, a South Korean drug developer of osteoarthritis therapeutics; and RMC, a distributor of specialized medical devices. Vaximm AG, a venture spun out from Merck KGaA, has completed Phase 2a clinical trials for glioblastoma. Darnatein, established by Dr. Seung-Hyun Choi, a former researcher at one of the leading research institutes in the U.S., Salk Institute for Biological Studies, boasts a robust platform for cartilage and bone regeneration and is developing new drugs for other diverse disease indications based on this foundational technology. SillaJen boasts a diverse pipeline of new drugs, including the SJ-600 series and BAL0891, and is leading the way in developing anti-cancer viruses based on its GEEV® platform. Known for its immune-evasion capabilities, GEEV® enables anti-cancer viruses to efficiently target affected areas. The SJ-600 series is an anti-cancer pipeline based on SillaJen's GEEV® platform. BAL0891, a mitotic checkpoint inhibitor, has advanced to Phase 1 clinical trials targeting solid tumors and will be conducted in the United States. Sung Jae "Alex" Yu, COO of OSR Holdings, stated, "the signing of this MOU marks the two companies transitioning into strategic partners for the development of innovative drug technologies in the global immuno-oncology market. We eagerly anticipate exploring a variety of opportunities to further our relationship and collaborations with SillaJen, particularly in the U.S., the largest pharmaceutical market in the world." A representative of SillaJen stated, "We can anticipate synergies by collaborating between a company that possesses original anti-cancer drug development technology and a company with global business expertise," and added, "Aside from our cooperation with existing partners, we will have the opportunity to present SillaJen's exceptional pipeline in the U.S. market." About OSR Holdings OSR Holdings, headquartered in Korea, is a global healthcare holding company with biopharma and medical device subsidiaries in areas with high unmet medical needs such as certain cancer indications. The biopharma subsidiaries are developing novel drug candidates based on differentiated technologies. The medical device subsidiary operates as an exclusive distributor of neuro-intervention devices to nationwide hospitals in Korea. In November 2023, OSR Holdings announced a business combination with Bellevue Life Sciences Acquisition Corp (Nasdaq: BLAC), a SPAC that completed a $69M IPO in February 2023. About SillaJen SillaJen, Inc. (KOSDAQ: 215600) is a publicly held biotech company developing anti-cancer therapies, with its clinical-stage products, Pexa-Vec, an oncolytic viral immunotherapy, and BAL0891, a mitotic checkpoint inhibitor. The company is also developing a unique CD-55 expressing vaccinia virus platform, GEEV®, which can be delivered to tumors via intravenous injection while evading the complement system and neutralizing antibodies against oncolytic viruses. Additional information about SillaJen is available at . Disclaimer Language: This press release contains certain forward-looking statements regarding, among other things, statements relating to goals, plans and projections regarding the Company's financial position, results of operations, market position, product development and business strategy. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and OSR Holdings undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. SOURCE OSR Holdings

MORRISVILLE, N.C., May 8, 2023 /PRNewswire/ -- Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, announced the appointment of Dr. Matthias Schroff as CEO effective today. Dr. Schroff will also join the Board of Directors. Dr. Schroff succeeds Mr. Shailesh Maingi, who will remain as Executive Chairman. Dr. Schroff has extensive biopharmaceutical leadership experience with a track record of success building companies and developing new medicines in immuno-oncology, inflammatory diseases, and genetic disorders. Dr. Schroff was most recently Chief Executive Officer of Exicure, a publicly traded biotechnology company developing gene regulatory and immunotherapeutic drugs. Prior to his role at Exicure, Dr. Schroff was the Chief Executive Officer of Vaximm AG and held several positions on management levels at Mologen, ultimately rising to Chief Executive Officer. Dr. Schroff earned a degree in Biochemistry at the University of Leibniz University Hannover and his Doctorate of Molecular Biology from Freie University Berlin. "I am excited about the next chapter for the company under Matthias's leadership," said Mr. Maingi. "I am proud of the team we have built and all that we have accomplished together. Matthias's background and expertise in leading teams to success is a perfect fit for this stage of Inceptor's growth." "I am thrilled to be taking on this new role at such an important time," said Dr. Schroff. "Inceptor Bio's commitment to advancing a diversified pipeline of cell therapies is highly differentiated, and I am excited to join the team at this important inflection point." About Inceptor Bio Founded in 2020, Inceptor Bio is a biotechnology company strategically advancing a pipeline of diversified cell therapies in oncology. Inceptor is developing CAR-T, CAR-M, & CAR-NK products engineered for optimal efficacy against solid tumors. Additional information about Inceptor Bio is available at . Media Contact Abe Maingi [email protected] SOURCE Inceptor

New York, July 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Neoantigen Cancer Vaccine Market, By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2026" - Global neoantigen cancer vaccine market is projected to grow with a CAGR of 54.18% during the forecast period and is expected to reach USD1754.44 million by 2026. The key factors responsible for the growth of neoantigen cancer vaccine market include rapid innovations in technology as well as infrastructural developments in healthcare sector. Additionally, growing investments by the governing bodies and healthcare providers is another major factor that is anticipated to boost the growth of neoantigen cancer vaccine market across the globe in the coming years.The global neoantigen cancer vaccine market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region, and company.Based on route of administration, the market can be segmented into intravenous, intramuscular, transdermal and others.Out of which, the intravenous segment is expected to dominate the market through 2026 and intramuscular is anticipated to be the fastest growing segment in the forecast period.This growth can be accredited to quick response as well as to the fact that drug dosage can be controlled easily.Along with that, intramuscular injections can be used rather than intravenous because some drugs cause irritation to veins when injected intravenously. This is expected to result in high growth of intramuscular route of administration segment in the coming years.The application segment is further segregated into lung, melanoma, gastrointestinal, brain cancer, and others.The lung cancer segment is going to dominate the market in the forecast period as the neoantigen based immunotherapy of OSE Immunotherapeutics, which is in development for the Tedopi (OSE2101) neoantigen cancer vaccine is expected to launch in 2022.Tedopi (OSE2101), is used in the treatment of HLA-A2+ Lung cancer (NSCLC) patients. Currently, the vaccine is in phase III stage of clinical development.Regionally, Asia Pacific neoantigen cancer vaccine market is expected to be the leading region over the forecast period due to the rising prevalence and incidence of cancer cases including lung cancer, melanoma, gastrointestinal, pancreatic cancer and other solid tumor indications.Major players operating in the global neoantigen cancer vaccine market include OSE Immunotherapeutics SA, Gritstone bio, Inc., BioNTech SE, F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., Moderna Inc., Avidea Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co., Ltd., Vaximm AG, Medigene AG, Genocea Biosciences Inc., Advaxis, Inc., Nouscom AG, among others are the leading players operating in global neoantigen cancer vaccine market. The companies operating in the market across the globe are focusing more towards expanding their share in the market.Years considered for this report:Base Year: 2020Estimated Year: 2022Forecast Period: 2023-2026Objective of the Study:• To analyze and forecast the market size of global neoantigen cancer vaccine market.• To classify and forecast global neoantigen cancer vaccine market based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, company and regional distribution from 2021 to 2026 and growth rate until 2026.• To identify drivers and challenges for global neoantigen cancer vaccine market.• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global neoantigen cancer vaccine market.• To conduct pricing analysis for global neoantigen cancer vaccine market.• To identify and analyze the profile of leading players operating in global neoantigen cancer vaccine market.The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of manufacturers across the globe.Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.Through this technique, the analyst could include the manufacturers which could not be identified due to the limitations of secondary research. The analyst examined the new products, distribution channels and presence of all major players across the globe.The analyst calculated the market size of global neoantigen cancer vaccine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.Key Target Audience:• Neoantigen cancer vaccine manufacturers and other stakeholders• Government bodies such as regulating authorities and policy makers• Organizations, forums and alliances related to neoantigen cancer vaccine• Market research and consulting firmsThe study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.Report Scope:In this report, global neoantigen cancer vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:• Global Neoantigen Cancer Vaccine Market, By Product:o Personalized neo-antigen vaccineo Off-the shelf neoantigen vaccine• Global Neoantigen Cancer Vaccine Market, By Neoantigen Type:o Synthetic Long Peptideo Nucleic acido Dendritic cello Tumor cell• Global Neoantigen Cancer Vaccine Market, By Route of Administration:o Intravenouso Intramuscularo Transdermalo Others• Global Neoantigen Cancer Vaccine Market, By Cell:o Autologouso Allogenic• Global Neoantigen Cancer Vaccine Market, By Technology:o RNA Sequencingo Whole Genome Sequencingo HLA Typing• Global Neoantigen Cancer Vaccine Market, By Delivery Mechanism:o Liposomeso Virosomeso Gene guno Electroporationo Others• Global Neoantigen Cancer Vaccine Market, By Application:o Lungo Melanomao Gastrointestinalo Brain cancero Others• Global Neoantigen Cancer Vaccine Market, By Region:o North America United States Canada Mexicoo Europe Germany France United Kingdom Italy Spaino Asia-Pacific China India Japan Australia South Korea Singaporeo South America Brazil Argentina Colombiao Middle East and Africa South Africa Saudi Arabia UAECompetitive LandscapeCompany Profiles: Detailed analysis of the major companies present in global neoantigen cancer vaccine market.Available Customizations:With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:Company Information• Detailed analysis and profiling of additional market players (up to five).Read the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________